Revisiting the "never trust a biotech that changes its name" theme, a splendid piece of puffery from TXBI -
HOUSTON--(BUSINESS WIRE)--May 16, 2003--Texas Biotechnology Corporation (Nasdaq:TXBI - News) today announced, following approval by its shareholders, the change of its corporate name to Encysive Pharmaceuticals, effective today. In conjunction with the name change, on May 19 the company's Nasdaq ticker symbol will change to "ENCY" and its corporate Web site address will become www.encysive.com.
"Our new identity better reflects our optimism, strategic focus and aspirations to achieve profitability (and inability to spell)," said Bruce D. Given, M.D., president and CEO of Encysive Pharmaceuticals. "Changing our name to Encysive Pharmaceuticals should facilitate our efforts as we reach out to new audiences in our drive towards commercialization of sitaxsentan, our once daily, selective endothelin antagonist for the treatment of pulmonary arterial hypertension."... |
